Riskpilot← Back to searchSign inGet full accessScandion Oncology A/S
A/SIn liquidationCVR 38613391Fruebjergvej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20171 employeeshttp://scandiononcology.com/
Revenue 2024
—
EBITDA margin
—
+9% vs 2023
Equity ratio
45.2%
Financial strength
Net profit 2024
DKK -36,7M
+6% vs 2023
| Revenue | — | — |
| EBITDA | DKK -41,1M | +9% |
| Net profit | DKK -36,7M | +6% |
| Total assets | DKK 18,3M | -47% |
| Equity | DKK 8,3M | -73% |
| Employees | 1 | — |
Legal name
Scandion Oncology A/S
CVR number
38613391
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. maj 2017
Share capital
DKK 17.271.840
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at forske, udvikle, producere og sælge lægemidler og lægemiddelkandidater, relaterede teknologier, service og andre beslægtede forretningsområder efter bestyrelsens skøn.
Address
Fruebjergvej 3
Phone
+4538102017
Email
info@scandiononcology.com
Website
http://scandiononcology.com/
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | — | — | — | — |
| Staff expenses | -9.396 | -0 | -0 | -0 | -0 |
| EBITDA | -22.852 | -55.367 | -80.166 | -45.357 | -41.148 |
| Depreciation & amort. | -36 | -0 | -0 | -0 | -0 |
| EBIT | -22.888 | -55.367 | -80.166 | -45.357 | -41.148 |
| Net financials | 2.235 | -1.846 | -2.034 | 653 | 236 |
| Profit before tax | -20.653 | -57.213 | -82.200 | -44.704 | -40.912 |
| Tax | -4.384 | -5.508 | -5.500 | -5.500 | -4.254 |
| Net profit | -16.269 | -51.705 | -76.700 | -39.204 | -36.658 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 186.408 | 116.219 | 89.401 | 34.560 | 18.279 |
| Equity | 155.865 | 104.541 | 70.327 | 31.122 | 8.268 |
| Long-term debt | 509 | 584 | 821 | 0 | 0 |
| Short-term debt | 30.026 | 11.094 | 18.254 | 3.438 | 10.011 |
| Total debt | 30.535 | 11.678 | 19.075 | 3.438 | 10.011 |
EBITDA margin
-4114800000.0%
This company
15.8%
Market median
-26043038075% vs market
20202024
Equity ratio
45.2%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
-443.4%
This company
18.4%
Market median
-2510% vs market
20202024
Net profit margin
-3665800000.0%
This company
8.1%
Market median
-45256790223% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.21×
This company
0.62×
Market median
-95% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
NA Founder | Founder | 2017 |
JS Unofficial title | Unofficial title | 2025 |
JS Founder | Founder | 2017 |
KA Founder | Founder | 2017 |
| Former (2) | ||
FM Chief Executive Officer | Chief Executive Officer | 2023 – 2025 |
JB Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (12) | ||
| Deputy Chairman | 2019 – 2024 | |
| Chairman | 2019 – 2022 | |
| Deputy Chairman | 2018 – 2019 | |
| Board of Directors | 2017 – 2022 | |
| Chairman | 2022 – 2025 | |
| Board of Directors | 2022 – 2024 | |
| Deputy Chairman | 2024 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2017 – 2022 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2024 – 2024 | |
| Board of Directors | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5–9.99% | 5–9.99% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Scandion Oncology A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Francois-Regis Marie Eugene Martelet | Chief Executive Officer | 0 companies |
| Nils Aage Brünner | Founder | 0 companies |
| Jens Bo Rode Hansen | Chief Executive Officer | 0 companies |
| Johnny Stilou | Unofficial title | 0 companies |
| Jan Stenvang | Founder | 0 companies |
| Kim Arvid Nielsen | Founder | 0 companies |
| Jørgen Vilhelm Løvenørn Bardenfleth | Deputy Chairman | 0 companies |
| Peter Høngård Andersen | Chairman | 0 companies |
| Thomas Feldthus | Deputy Chairman | 0 companies |
| Karl Arne Krister Borrebaeck | Board of Directors | 0 companies |
| Martin Brygger Møller | Chairman | 0 companies |
| Martine Jannigje van Vugt | Board of Directors | 0 companies |
| Alejandra Maria Cristina Bonifacini Mørk | Deputy Chairman | 0 companies |
| Keld Flintholm Jørgensen | Board of Directors | 0 companies |
| Christian Vinding Thomsen | Board of Directors | 0 companies |
| Per Pfeiffer | Board of Directors | 0 companies |
| Michel Pierre Ducreux | Board of Directors | 0 companies |
| Annie Rasmussen | Board of Directors | 0 companies |